Otsuka zips into adjuvant use
As a second-line zipalertinib filing approaches, Otsuka goes earlier and broader.
A mystery Moderna asset hits the clinic
mRNA-2808 could be a multispecific mRNA-encoded T-cell engager therapy.
Astellas and Amgen join the pan-KRAS push
Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.
Pfizer’s Global Blood buy fails to Thrive
Inclacumab fails, and osivelotor is on hold.
More conjugates pile into the clinic
J&J, Astra, Pfizer and others move yet more ADCs into human studies.
CatalYm joins Pfizer in pivotal cachexia push
Shortly after ponsegromab, visugromab is to start phase 2/3.
